论文部分内容阅读
目的探讨三氧化二砷治疗肝癌的临床效果及安全性。方法收集我院自2010年12月～2012年12月收治的44例肝癌患者,其中26例采用三氧化二砷静脉滴注治疗,其余18例姑息手术治疗后采用三氧化二砷微量化疗,观察患者临床缓解率、生化指标、影像学、生活质量改善及不良反应发生情况。结果 44例患者经4～6个疗程治疗后,完全缓解8例,部分缓解22例,稳定8例,进展6例,治疗总有效率为68.2%;有81.8%患者生活质量改善或稳定;其中6例患者在接受2周治疗后肿块明显缩小,15例患者治疗1周后AFP明显下降,治疗前后指标均有明显差异,P<0.05;患者治疗中3例出现呕吐、恶心,7例出现乏力,4例出现骨髓抑制,不良反应发生率为31.8%。结论三氧化二砷治疗肝癌效果显著,促进患者生活质量的提高,值得推广使用。
Objective To investigate the clinical effect and safety of arsenic trioxide in the treatment of liver cancer. Methods Forty-four patients with hepatocellular carcinoma who were admitted to our hospital from December 2010 to December 2012 were enrolled. Among them, 26 patients were treated with intravenous infusion of arsenic trioxide, and the remaining 18 patients received palliative treatment with arsenic trioxide. The clinical response rate, biochemical Indicators, imaging, quality of life improvement and adverse reactions. Results After treatment of 44 patients with 4 to 6 courses of complete remission in 8 cases, partial remission in 22 cases, stable in 8 cases, progress in 6 cases, the total effective rate was 68.2%; 81.8% of patients with quality of life improved or stable; of which 6 patients underwent 2 weeks after the treatment of tumor was significantly reduced, 15 patients after treatment for 1 week significantly decreased AFP, before and after treatment were significantly different indicators, P <0.05; 3 cases of patients with vomiting, nausea, 7 cases of fatigue , 4 cases of bone marrow suppression occurred, the incidence of adverse reactions was 31.8%. Conclusion Arsenic trioxide is effective in treating HCC and promotes the improvement of patients’ quality of life. It is worth promoting.